tbuckley/cabot-search huggingface dataset:
COMPARING THE CLINICAL OUTCOME OF PATIENTS UNDERGOING CONTACT FORCE GUIDED RADIOFREQUENCY AND SECOND GENERATION CRYOBALLOON ABLATION
Authors: Zahra Azizi, Pouria Alipour, Rebecca Malcolm, Sarah Donegan, Sereena Nath, Farzaneh Sharifzad, Gabrielle Falvey, Jamie Forman, Kaitlin Stitz, Samani Alireza, Jenny Gao-Kang, Nikhil Nath, Negar Sayrafizadeh, Farhad sayrafizadeh, Rohan Dadak, Amirhossein Sharifzad, Nicole Mogadasian, Zainab Rasti-Lari, Sara Tamjidi, Sadra Taheri, Roshni Kohli, Gabi Jacobson, Alfredo Pantano, Atul Verma, Yaariv Khaykin
Journal: Journal of the American College of Cardiology (2021)
LONG-TERM TRANSPLANT-FREE SURVIVAL AFTER CONGENITAL HEART SURGERY
Authors: Lazaros Kochilas, Amanda Thomas, Chao Zhang, J’Neka Claxton, Courtney McCracken, James St Louis, James Moller, Alvaro Alonso, Logan Spector, Fawwaz Shaw, Yijian Huang
Journal: Journal of the American College of Cardiology (2021)
THE USE OF MULTIPLE ARTERIAL GRAFTS IN CORONARY ARTERY BYPASS GRAFTING IS ASSOCIATED WITH DECREASED POST-OPERATIVE RENAL FAILURE AND STROKE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Authors: Ana Velez, Eric Etchill, Katherine Giuliano, Hamza Aziz, Ahmet Kilic, Stefano Schena, Jennifer Lawton, Chun Choi
Journal: Journal of the American College of Cardiology (2021)
HEALTHCARE RESOURCE UTILIZATION IN PATIENTS TREATED WITH EMPAGLIFLOZIN IN EAST ASIA: RESULTS FROM EMPRISE STUDY
Authors: Wayne Sheu, Yutaka Seino, Elise Tan, Daisuke Yabe, Kyoung Hwa Ha, Wook-Jin Chung, Yusuke Taneda, Wei-Yu Lei, Anastasia Ustyugova, Riho Klement, Anouk Deruaz-Luyet, Moe Kyaw, Dae Jung Kim
Journal: Journal of the American College of Cardiology (2021)
Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
Authors: Benjamin N. Rome, William B. Feldman, Rishi J. Desai, Aaron S. Kesselheim
Journal: JAMA Network Open (2021)

<h3>Importance</h3> List prices set by manufacturers for brand-name prescription drugs in the US have been increasing faster than inflation, although confidential manufacturer rebates offset some of these increases. Most commercially insured patients pay at least some out-of-pocket costs for prescription drugs, and higher patient spending is associated with lower adherence and worse health outcomes. <h3>Objective</h3> To examine whether price changes for brand-name drugs are correlated with changes in patient out-of-pocket spending and whether this association varies by insurance benefit design. <h3>Design, Setting, and Participants</h3> A cohort study of 79 brand-name drugs with available pricing data from January 2015 to December 2017 was conducted, with data obtained from a national commercial insurance claims database. <h3>Exposures</h3> Change in the list prices set by manufacturers and estimated net prices after rebates among non-Medicaid payers. <h3>Main Outcomes and Measures</h3> Change in median out-of-pocket spending among all patients and stratified by insurance pharmacy benefit design, including high-deductible insurance plans and plans with any amount of deductibles or coinsurance. <h3>Results</h3> Among 79 drugs, median increases were 16.7% (interquartile range [IQR], 13.6%-21.1%) for list prices, 5.4% (IQR, −3.9% to 11.7%) for net prices, and 3.5% (IQR, 1.4%-9.1%) for out-of-pocket spending from 2015 to 2017. Changes in list prices were correlated with changes in net prices (<i>r</i> = 0.34;<i>P</i> = .002). Overall, changes in out-of-pocket spending were not correlated with changes in list prices (<i>r</i> = 0.14;<i>P</i> = .22) or net prices (<i>r</i> = 0.04;<i>P</i> = .71). Among 53.7% of patients who paid any drug deductible or coinsurance, median out-of-pocket spending increased by 15.0%, and changes were moderately correlated with changes in list prices (<i>r</i> = 0.38;<i>P</i> = .001) but not net prices (<i>r</i> = 0.06;<i>P</i> = .62). <h3>Conclusions and Relevance</h3> Some commercially insured patients who pay only prescription drug copayments appear to be insulated from increases in drug prices. However, more than half of patients pay deductibles or coinsurance and may experience substantial increases in out-of-pocket spending when drug prices increase. Among these patients, there was no evidence that manufacturer rebates to insurers are associated with patients' out-of-pocket spending. Policies to rein in unregulated annual increases in list prices for brand-name drugs may have important consequences for patient out-of-pocket spending.
THE ROLE OF CLINICAL PRESENTATION AND ELECTROCARDIOGRAM CHANGES IN DIAGNOSING HYPERKALEMIA
Authors: Abdel-Hameed Al-Mistarehi, Liqaa A. Raffee, Radwan Mashina, Muhannad J. Ababneh, Mahmoud M. Aboozour, Musaab K. Ali
Journal: Journal of the American College of Cardiology (2021)
TAPERING AND DISCONTINUATION OF BACKGROUND THERAPIES DURING THE TRANSITION TO RILONACEPT MONOTHERAPY IN RHAPSODY, A PHASE 3 CLINICAL TRIAL OF RILONACEPT IN PATIENTS WITH RECURRENT PERICARDITIS
Authors: Antonio Brucato, Alistair Wheeler, Sushil Luis, Antonio Abbate, Paul Cremer, Fang Fang, Antonella Insalaco, Martin LeWinter, Basil S. Lewis, David Lin, Stephen J. Nicholls, Allan Klein, Massimo Imazio, John F. Paolini
Journal: Journal of the American College of Cardiology (2021)
Biodegradability of Micro/Nanomotors: Challenges and Opportunities
Authors: Shuanghu Wang, Jia Xu, Quan Zhou, Peiwu Geng, Bo Wang, Yunfang Zhou, Kun Liu, Fei Peng, Yingfeng Tu
Journal: Advanced Healthcare Materials (2021)

Abstract Micro/nanomotors (MNMs) are miniature machines that can convert chemical or external energy into their own mechanical motions. In previous decades, significant efforts have been made to improve the performance of MNMs. For practical applications, the biodegradability of MNMs is an important aspect that must be considered, particularly in the biomedical field. In this review, recent progress in the biodegradability of MNMs and their potential applications are summarized. Different biodegradable materials, including metals and polymers, or other strategies for the fabrication of MNMs, are presented. Current challenges and future perspectives are also discussed.
AORTIC INTIMAL DISRUPTION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Anuj Mediratta, Islamiyat Babs Animashaun, Philippe Genereux, Leo Marcoff, Konstantinos Koulogiannis, Seth Uretsky, Robert Kipperman, John Brown, Linda Gillam
Journal: Journal of the American College of Cardiology (2021)
LOW-INTENSITY FOCUSED ULTRASOUND ON RENAL SYMPATHETIC NERVE PREVENT MYOCARDIAL INFARCTION INDUCED SYMPATHETIC NEURAL ACTIVATION AND VENTRICULAR ARRHYTHMIAS IN CANINES
Authors: Mingxian Chen, Songyun Wang, Zhuo Wang, Xin Lai, Shenghua Zhou
Journal: Journal of the American College of Cardiology (2021)
DIRECT IMPLANTATION OF A SUPRA-ANNULAR SELF-EXPANDING BIOPROSTHESES HAS NO IMPACT ON ONE-YEAR ECHOCARDIOGRAPHIC OUTCOMES
Authors: Georgios Benetos, Maria Karmpalioti, Maria Drakopoulou, Konstantinos Stathogiannis, Maria Xanthopoulou, George Latsios, Andreas Synetos, Evangelia Bei, Vassilis Voudris, Elias Kosmas, Georgios Katsimagklis, Vicki Zeniou, Haim Danenberg, Manolis Vavuranakis, Dimitris Tousoulis, Konstantinos Tsioufis, Konstantinos Toutouzas
Journal: Journal of the American College of Cardiology (2021)
PATISIRAN STABILIZES CARDIAC MECHANICS IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS: POST-HOC ANALYSIS OF THE APOLLO STUDY
Authors: Hannah Rosenblum, Jan Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest, Matthew White, Scott Solomon, Daniel Burkhoff, Mathew Maurer
Journal: Journal of the American College of Cardiology (2021)
Rates of Serious Surgical Errors in California and Plans to Prevent Recurrence
Authors: Andrew J. Cohen, Hansen Lui, Micha Zheng, Bhagat Cheema, German Patino, Michael A. Kohn, Anthony Enriquez, Benjamin N. Breyer
Journal: JAMA Network Open (2021)

Despite widespread recognition and known harms, serious surgical errors, known as surgical never events, endure. The California Department of Public Health (CDPH) has developed an oversight system to capture never events and a platform for process improvement that has not yet been critically appraised.To examine surgical never events occurring in hospitals in California and summarize recommendations to prevent future events.This cross-sectional study identified 386 CDPH hospital administrative penalty reports, of which 142 were ascribable to never events occurring during surgery. These never events were identified and summarized from January 1, 2007, to December 31, 2017. A directed qualitative approach was used to analyze CDPH-mandated corrective steps to reduce future errors in this multicenter study of all accredited hospitals in California. Inclusion of surgical never event records was based on definitions established by the US Department of Health and Human Services National Quality Forum. Data analysis was performed from January 1, 2019, to November 30, 2020.Never events include death or disability of an American Society of Anesthesiologists class I patient, wrong site or wrong surgery, retained foreign objects, burns, equipment failure leading to intraoperative injury, nonapproved experimental procedures, insufficient surgeon presence or privileges, or fall from the operating room table.Incident rates, consequences, and improvement plans to prevent additional never events were outcomes of interest.A total of 142 never events were reported to the CDPH (1 per 200 000 operations). Annual surgical volume for hospitals with events was 9203 vs 3251 cases for hospitals without events (P < .001). A total of 94 of 142 events (66.2%) were retained foreign objects ranging from Kocher clamps to drain sponges. Wrong site or patient surgery accounted for 22 events (15.5%), surgical burns for 11 (7.7%), and other for 15 (10.6%). Other included insufficient surgeon presence, equipment failure, or falls in the operating room. Improvement plans included 18 unique categories of recommendations from regulators, many focusing on proper use of checklists. Regulators mandated a mean (SD) of 13 (7) corrective actions in the improvement plans. Policy adherence monitoring (119 [90.2%]), revision of existing policy (84 [63.6%]), and education regarding policy (83 [62.9%]) were common action items, whereas disciplinary action toward staff was rare (11 [8.3%]).Surgical never events are a rare issue in California. Numerous strategies have evolved to reduce errors, many involving the thorough and proper use of intraoperative checklists.
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations
Authors: Romain Paccoud, Céline Saint-Laurent, Enzo Piccolo, Mylène Tajan, Alizée Dortignac, Ophélie Pereira, Sophie Le Gonidec, Inès Baba, Adélaïde Gélineau, Haoussa Askia, Maxime Branchereau, Julie Charpentier, Jean Personnaz, Sophie Branka, Johanna Auriau, Simon Deleruyelle, Mickaël Canouil, Nicolas Beton, Jean-Pierre Salles, Maithé Tauber, Jacques Weill, Philippe Froguel, Benjamin G. Neel, Toshiyuki Araki, Christophe Heymes, Rémy Burcelin, Isabelle Castan, Philippe Valet, Cédric Dray, Emmanuel L. Gautier, Thomas Edouard, Jean-Philippe Pradère, Armelle Yart
Journal: Science Translational Medicine (2021)

Hyperactive SHP2 promotes inflammation-driven insulin resistance by skewing macrophage balance in metabolic tissues and may be a target in T2D.
THERAPY-INDUCED IMPROVEMENT IN CORONARY COLLATERAL CIRCULATION AND CHANGES IN MYOCARDIAL MECHANICS DURING EXERCISE STRESS ECHO: THE CARHEXA SUB STUDY
Authors: Marija Petrovic, Vojislav Giga, Nikola Boskovic, Srdjan Dedic, Branko Beleslin, Eugenio Picano, Ana Djordjevic Dikic
Journal: Journal of the American College of Cardiology (2021)
IMPACT OF ANEMIA ON IN-HOSPITAL OUTCOMES OF MYOCARDIAL INFARCTION: A NATIONAL DATABASE ANALYSIS
Authors: Aravdeep Jhand, Hyo Jung Tak, Arslan Ahmed, Eirini Apostolidou, S. Elissa Altin, Matthew Sherwood, Sunil Rao, Jeffrey Carson, Li-Wu Chen, J. Abbott, Andrew Goldsweig
Journal: Journal of the American College of Cardiology (2021)
Best practices on the differential expression analysis of multi-species RNA-seq
Authors: Matthew Chung, Vincent M. Bruno, David A. Rasko, Christina A. Cuomo, José F. Muñoz, Jonathan Livny, Amol C. Shetty, Anup Mahurkar, Julie C. Dunning Hotopp
Journal: Genome biology (2021)

Abstract Advances in transcriptome sequencing allow for simultaneous interrogation of differentially expressed genes from multiple species originating from a single RNA sample, termed dual or multi-species transcriptomics. Compared to single-species differential expression analysis, the design of multi-species differential expression experiments must account for the relative abundances of each organism of interest within the sample, often requiring enrichment methods and yielding differences in total read counts across samples. The analysis of multi-species transcriptomics datasets requires modifications to the alignment, quantification, and downstream analysis steps compared to the single-species analysis pipelines. We describe best practices for multi-species transcriptomics and differential gene expression.
ULTRASOUND OF THE INTERNAL JUGULAR VEIN (UJVP) WITH POINT OF CARE ULTRASOUND (POCUS) CORRELATES WITH ELEVATED RIGHT ATRIAL PRESSURE (RAP) ON RIGHT HEART CATHETERIZATION (RHC) IN PREDICTING 6-MONTH MORTALITY
Authors: Lillian Lei Ching Khor, Libo Wang, Jonathan Harrison, Nijat Alijev, Elizabeth Dranow
Journal: Journal of the American College of Cardiology (2021)
Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer
Authors: Kai-Li Zhang, Wen-Wei Zhu, Sheng-Hao Wang, Chao Gao, Jun-Jie Pan, Zun-Guo Du, Lu Lu, Hu-Liang Jia, Qiong-Zhu Dong, Jin-Hong Chen, Ming Lu, Lun-Xiu Qin
Journal: Theranostics (2021)

Rationale: Metastasis, the development of secondary malignant growth at a distance from a primary tumor, is the main cause of cancer-associated death. However, little is known about how metastatic cancer cells adapt to and colonize in the new organ environment. Here we sought to investigate the functional mechanism of cholesterol metabolic aberration in colorectal carcinoma (CRC) liver metastasis. Methods: The expression of cholesterol metabolism-related genes in primary colorectal tumors (PT) and paired liver metastases (LM) were examined by RT-PCR. The role of SREBP2-dependent cholesterol biosynthesis pathway in cell growth and CRC liver metastasis were determined by SREBP2 silencing in CRC cell lines and experimental metastasis models including, intra-splenic injection models and liver orthotropic injection model. Growth factors treatment and co-culture experiment were performed to reveal the mechanism underlying the up-regulation of SREBP2 in CRC liver metastases. The in vivo efficacy of inhibition of cholesterol biosynthesis pathway by betulin or simvastatin were evaluated in experimental metastasis models. Results: In the present study, we identify a colorectal cancer (CRC) liver metastasis-specific cholesterol metabolic pathway involving the activation of SREBP2-dependent cholesterol biosynthesis, which is required for the colonization and growth of metastatic CRC cells in the liver. Inhibiting this cholesterol biosynthesis pathway suppresses CRC liver metastasis. Mechanically, hepatocyte growth factor (HGF) from liver environment activates SREBP2-dependent cholesterol biosynthesis pathway by activating c-Met/PI3K/AKT/mTOR axis in CRC cells. Conclusion: Our findings support the notion that CRC liver metastases show a specific cholesterol metabolic aberration. Targeting this cholesterol biosynthesis pathway could be a promising treatment for CRC liver metastasis.
Gait speed and adverse outcomes following hospitalised exacerbation of COPD
Authors: Jessica A. Walsh, Ruth E. Barker, Samantha S.C. Kon, Sarah E. Jones, Winston Banya, Claire M. Nolan, Suhani Patel, Oliver Polgar, Brigitte M. Haselden, Michael I. Polkey, Paul Cullinan, William D-C. Man
Journal: European Respiratory Journal (2021)

Background The 4-m gait speed (4MGS) test is a simple physical performance measure and surrogate marker of frailty that is associated with adverse outcomes in older adults. We aimed to assess the ability of 4MGS to predict prognosis in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Methods 213 participants hospitalised with AECOPD (52% male, mean age 72 years and mean forced expiratory volume in 1 s (FEV 1 ) 35% predicted) were enrolled. 4MGS and baseline demographics were recorded at hospital discharge. All-cause readmission and mortality were collected for 1 year after discharge and multivariable Cox proportional hazards regressions were performed. Kaplan–Meier and competing risks analyses were conducted comparing time to all-cause readmission and mortality between 4MGS quartiles. Results 111 participants (52%) were readmitted and 35 (16%) died during the follow-up period. 4MGS was associated with all-cause readmission, with an adjusted subdistribution hazard ratio of 0.868 (95% CI 0.797–0.945; p=0.001) per 0.1 m·s −1 increase in gait speed, and with all-cause mortality, with an adjusted subdistribution hazard ratio of 0.747 (95% CI 0.622–0.898; p=0.002) per 0.1 m·s −1 increase in gait speed. Readmission and mortality models incorporating 4MGS had higher discrimination than age or FEV 1 % pred alone, with areas under the receiver operator characteristic curves of 0.73 and 0.80, respectively. Kaplan–Meier and competing risks curves demonstrated that those in slower gait speed quartiles had reduced time to readmission and mortality (log-rank, both p&lt;0.001). Conclusions 4MGS provides a simple means of identifying at-risk patients with COPD at hospital discharge. This provides valuable information to plan post-discharge care and support.
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology
Authors: Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri-Kordestani, Julia A. Beaver, Lola Fashoyin-Aje, Nicole J. Gormley, Adnan A. Jaigirdar, Steven J. Lemery, Pallavi S. Mishra-Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur
Journal: Clinical Cancer Research (2021)

The FDA Oncology Center of Excellence (OCE) is a leader within the agency in scientific outreach activities and regulatory science research. On the basis of analysis of scientific workshops, internal meetings, and publications, the OCE identified nine scientific priority areas and one cross-cutting area of high interest for collaboration with external researchers. This article describes the process for identifying these scientific interest areas and highlights funded and unfunded opportunities for external researchers to work with FDA staff on critical regulatory science challenges.
Building brain capital
Authors: Harris A. Eyre, Rym Ayadi, William Ellsworth, Gowri Aragam, Erin Smith, Walter D. Dawson, Agustin Ibanez, Cara Altimus, Michael Berk, Husseini K. Manji, Eric A. Storch, Marion Leboyer, Naoko Kawaguchi, Michael Freeman, Patrick Brannelly, Facundo Manes, Sandra B. Chapman, Jeffrey Cummings, Carol Graham, Benjamin F. Miller, Zoltan Sarnyai, Retsina Meyer, William Hynes
Journal: Neuron (2021)
PRECLINICAL EFFICACY STUDY IN A PORCINE MODEL FOR A NOVEL GENE THERAPY APPROACH TO PROMOTE CARDIOMYOCYTE PROLIFERATION IN ISCHEMIC CARDIOMYOPATHY
Authors: Kamal Kassem, Riham R.E. Abouleisa, Xian-Liang Tang, Qinghui Ou, Mitesh Solanki, Roberto Bolli, Tamer M.A. Mohamed
Journal: Journal of the American College of Cardiology (2021)
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
Authors: Ralf Buettner, Le Xuan Truong Nguyen, Corey Morales, Min-Hsuan Chen, Xiwei Wu, Lisa S. Chen, Dinh Hoa Hoang, Servando Hernandez Vargas, Vinod Pullarkat, Varsha Gandhi, Guido Marcucci, Steven T. Rosen
Journal: Journal of Hematology & Oncology (2021)

BCL-2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60-70% clinical response rates, the vast majority of patients inevitably suffer disease relapse, likely because of the persistence of drug-resistant LSCs. We previously reported preclinical activity of the ribonucleoside analog 8-chloro-adenosine (8-Cl-Ado) against AML blast cells and LSCs. Moreover, our ongoing phase I clinical trial of 8-Cl-Ado in patients with refractory/relapsed AML demonstrates encouraging clinical benefit. Of note, LSCs uniquely depend on amino acid-driven and/or fatty acid oxidation (FAO)-driven oxidative phosphorylation (OXPHOS) for survival. VEN inhibits OXPHOS in LSCs, which eventually may escape the antileukemic activity of this drug. FAO is activated in LSCs isolated from patients with relapsed AML.Using AML cell lines and LSC-enriched blast cells from pre-treatment AML patients, we evaluated the effects of 8-Cl-Ado, VEN and the 8-Cl-Ado/VEN combination on fatty acid metabolism, glycolysis and OXPHOS using liquid scintillation counting, a Seahorse XF Analyzer and gene set enrichment analysis (GSEA). Western blotting was used to validate results from GSEA. HPLC was used to measure intracellular accumulation of 8-Cl-ATP, the cytotoxic metabolite of 8-Cl-Ado. To quantify drug synergy, we created combination index plots using CompuSyn software. The log-rank Kaplan-Meier survival test was used to compare the survival distributions of the different treatment groups in a xenograft mouse model of AML.We here report that VEN and 8-Cl-Ado synergistically inhibited in vitro growth of AML cells. Furthermore, immunodeficient mice engrafted with MV4-11-Luc AML cells and treated with the combination of VEN plus 8-Cl-Ado had a significantly longer survival than mice treated with either drugs alone (p ≤ 0.006). We show here that 8-Cl-Ado in the LSC-enriched population suppressed FAO by downregulating gene expression of proteins involved in this pathway and significantly inhibited the oxygen consumption rate (OCR), an indicator of OXPHOS. By combining 8-Cl-Ado with VEN, we observed complete inhibition of OCR, suggesting this drug combination cooperates in targeting OXPHOS and the metabolic homeostasis of AML cells.Taken together, the results suggest that 8-Cl-Ado enhances the antileukemic activity of VEN and that this combination represents a promising therapeutic regimen for treatment of AML.